Last reviewed 2026-04-20 · How we verify

Drug: PF-07817883 (drug-pf-07817883)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Abdominal distension
• Diarrhoea
• Vessel puncture site bruise
• Headache
• Alanine aminotransferase increased
• Mouth haemorrhage
• Nausea
• Vomiting
• Feeling hot
• Dizziness
• Oropharyngeal pain
• Ingrown hair

Key clinical trials

• A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease (PHASE3)
• A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults (PHASE1)
• A Study to Learn If the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine Ibuzatrelvir in Healthy Adults (PHASE1)
• A Study to Learn PF-07817883 Blood Levels After Administration of Tablets of Study Drug to Healthy Adult Volunteers (PHASE1)
• A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized (PHASE2)
• A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults. (PHASE1)
• A Study to Learn About How Loss of Liver Function Affects the Blood Levels of the Study Medicine Called PF-07817883. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Drug: PF-07817883 CI brief — competitive landscape report
• Drug: PF-07817883 updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI